Skip To Main Content
This website is intended exclusively for healthcare professionals residing and/or working in Kuwait.
Campus
Campus

Understanding Autoimmune T1D disease & Different Stages

A trigger initiates an autoimmune attack on the beta cells of the pancreas through autoreactive T cells 10

T1D is an autoimmune disease caused by an autoimmune response against pancreatic beta cells3

T1D is not primarily a metabolic disease; in T1D, the immune system attacks pancreatic beta cells, hindering their ability to produce insulin3
The body is no longer able to produce insulin once beta cells have been destroyed by the immune system3
Lack of production of insulin leads to hyperglycaemia3
A criticial deficiency of insulin causes DKA to occur8, a traumatic event which can have a lasting negative impact on brain function 1,9

DKA,diabetic ketoacidosis; T1D, type 1 diabetes.

AUTOIMMUNE T1D CAN START LONG BEFORE SYMPTOMS ARISE1

The rate of autoimmune T1D progression varies significantly; it can take months to decades for symptoms to develop.1,6

70% of children with multiple autoantibodies progress to symptomatic autoimmune T1D within 10 years.*10

5-year risk of progressing to symptomatic autoimmune T1D (Stage 3)6:

From Stage 1

From Stage 2

The lifetime risk of progressing to symptomatic autoimmune T1D (Stage 3) from Stages 1 and 2 approaches 100%. 6




Screening can transform lives by detecting the condition before symptoms develop.6,8,9

IQR, interquartile range; T1D, type 1 diabetes.
*In a pooled analysis of three prospective cohort studies including children from Colorado, Finland and Germany, progression to autoimmune T1D at 10-year follow-up after autoantibody seroconversion in 585 children with multiple autoantibodies was 69.7% (95% CI, 65.1%-74.3%).10

Autoimmune T1D is a progressive condition; the decline of beta cell function can begin months to years before symptoms appear.1,5,6

People with autoimmune T1D progress through three clinically distinct stages as their beta cells are progressively destroyed.4,6,7



The lifetime risk of progressing to symptomatic autoimmune T1D (Stage 3) from Stages 1 and 2 approaches 100%. 6


Screening can transform lives by detecting the condition before symptoms develop.6,8,9

T1D, type 1 diabetes.
*Reversion to single autoantibody or negative status can occur in some people with previously confirmed multiple autoantibody positivity.4

References

  1. DiMeglio LA, Evans-Molina C, Oram RA. Lancet. 2018;391(10138):2449-246.
  2. Gregory GA, Robinson TIG, Linklater SE, et al. Lancet Diabetes Endocrinol. 2022;10(10):741-760.
  3. Wolfsdorf JI, Glaser N, Agus M, et al. Pediatr Diabetes. 2018;19(Suppl 27):155-177.
  4. Phillip M, Achenbach P, Addala A, et al. Diabetes Care. 2024;47(8):1276-1298.
  5. Marré ML, James EA, Piganelli JD. Front Cell Dev Biol. 2015;3:67.
  6. Insel RA, Dunne JL, Atkinson MA, et al. Diabetes Care. 2015;38(10):1964-1974.
  7. Sims EK, Besser REJ, Dayan C, et al. Diabetes. 2022;71(4):610-623.
  8. Narendran P. Diabetologia. 2019;62(1):24-27.
  9. Raab J, Haupt F, Scholz M, et al. BMJ Open. 2016;6(5):e011144.
  10. Ziegler AG, Rewers M, Simell O, et al. JAMA. 2013;309(23):2473-2479.
  11. Barker JM. J Clin Endocrinol Metab. 2006;91(4):1210-1217.
  12. Głowińska-Olszewska B, Szabłowski M, Panas P, et al. Front Endocrinol (Lausanne). 2020;11:476.
  13. Ludvigsson JF, Ludvigsson J, Ekbom A, et al. Diabetes Care. 2006;29(11):2483-2488.
  14. Skov J, Kuja-Halkola R, Magnusson PKE, et al. Eur J Endocrinol. 2022;186(6):677-685.
  15. Biondi B, Kahaly GJ, Robertson RP. Endocr Rev. 2019;40(3):789-824.
  16. Cárdenas-Roldán J, Rojas-Villarraga A, Anaya JM. BMC Med. 2013;11:73.
  17. Karges B, Prinz N, Placzek K, et al. Diabetes Care. 2021;44(5):1116-1124.
  18. Besser REJ, Bell KJ, Couper JJ, et al. Pediatr Diabetes. 2022;23(8):1175-1187.
  19. Morran MP, Vonberg A, Khadra A, et al. Mol Aspects Med. 2015;42:42-60.
  20. Muñoz C, Floreen A, Garey C, et al. Clin Diabetes. 2019;37(3):276-281.
  21. Allen LA, Taylor PN, Gillespie KM, et al. Lancet Diabetes Endocrinol. 2023;11(10):755-767.
  22. Weires MB, Tausch B, Haug PJ, et al. Exp Clin Endocrinol Diabetes. 2007;115(10):634-640.
  23. Parkkola A, Härkönen T, Ryhänen SJ, et al. Diabetes Care. 2013;36(2):348-354.
  24. Allen C, Palta M, D’Alessio DJ. Diabetes. 1991;40(7):831-836.
  25. American Diabetes Association. Genetics of diabetes. Accessed October 1, 2024. https://diabetes.org/about-diabetes/genetics-diabetes
  26. el-Hashimy M, Angelico MC, Martin BC, et al. Diabetes. 1995;44(3):295-299.
  27. Besser REJ, Ng SM, Gregory JW, et al. Arch Dis Child. 2022;107(9):790-795.
  28. Hummel S, Carl J, Friedl N, et al. Diabetologia. 2023;66(9):1633-1642.
  29. Tomic D, Craig ME, Magliano DJ, et al. Diabet Med. 2024;41(1):e15218.
  30. AbuHammad GAR, Naser AY, Hassouneh LKM. BMC Endocr Disord. 2023;23(1):102.
  31. Cameron FJ, Scratch SE, Nadebaum C, et al. Diabetes Care. 2014;37(6):1554-1562.
  32. Ghetti S, Kuppermann N, Rewers A, et al. Diabetes Care. 2020;43(11):2768-2775.
  33. Duca LM, Wang B, Rewers M, et al. Diabetes Care. 2017;40(9):1249-1255.
  34. Ziegler AG, Kick K, Bonifacio E, et al. JAMA. 2020;323(4):339-351.
  35. Elding Larsson H, Vehik K, Bell R, et al. Diabetes Care. 2011;34(11):2347-2352.
  36. Hekkala AM, Ilonen J, Toppari J, et al. Pediatr Diabetes. 2018;19(2):314-319.
  37. Winkler C, Schober E, Ziegler AG, et al. Pediatr Diabetes. 2012;13(4):308-313.
  38. Nakhla M, Cuthbertson D, Becker DJ, et al. JAMA Pediatr. 2021;175(5):518-520.
  39. TRIGR Study Group. Pediatr Diabetes. 2007;8(3):117-137.
  40. Barker JM, Goehrig SH, Barriga K, et al; DAISY study. Diabetes Care. 2004;27(6):1399-1404.
  41. Veijola R, Koskinen M, Helminen O, et al. Pediatr Diabetes. 2016;17(Suppl 22):25-30.
  42. Martinez MM, Spiliopoulos L, Salami F, et al. Clin Diabetes Endocrinol. 2022;7(1):23.
  43. Sousa GR, Pober D, Galderisi A, et al. Circulation. 2019;139(6):730-743.
  44. Zakir M, Ahuja N, Surksha MA, et al. Cureus. 2023;15(9):e45835.
  45. Fowler MJ. Clin Diabetes. 2008;26(2):77-82.
  46. Rawshani A, Sattar N, Franzén S, et al. Lancet. 2018;392(10146):477-486.
  47. Moore DJ, Leibel NI, Polonsky W, et al. Int J Gen Med. 2024;17:3003-3014.
  48. Quinn LM, Rashid R, Narendran P, et al. Br J Gen Pract. 2022;73(726):36-39.
  49. Rikos N, Mpalaskas A, Fragiadaki M, et al. Nurs Rep. 2022;12(3):564-573.
  50. Jönsson L, Lundqvist P, Tiberg I, et al. Scand J Caring Sci. 2015;29(1):126-135.
  51. Diabetes and emotional health - Chapter 3: Diabetes distress. Accessed October 1, 2024. https://professional.diabetes.org/sites/default/files/media/ada_mental_health_workbook_ chapter_3.pdf
  52. Ospelt E, Hardison H, Rioles N, et al. Clin Diabetes. 2024;42(1):17-26.
  53. AsktheExperts. T1D info for providers. Accessed October 1, 2024. https://asktheexperts.org/ for-providers
  54. Edelman S. J Fam Pract. 2023;72(Suppl 6):S19-S24.
  55. Juvenile Diabetes Research Foundation. New guidance sets out how to support people with early- stage type 1 diabetes. Published June 2024. Accessed October 1, 2024. https://jdrf.org.uk/ news/new-guidance-sets-out-how-to-support-people-with-early-stage-type-1-diabetes/
  56. ElSayed NA, Aleppo G, Aroda VR, et al. Diabetes Care. 2023;46(Suppl 1):S19-S40.
  57. Krischer JP; Type 1 Diabetes TrialNet Study Group. Diabetologia. 2013;56(9):1919-1924.
  58. Hope SV, Wienand-Barnett S, Shepherd M, et al. Br J Gen Pract. 2016;66(646):e315-322.
  59. Type 1 Diabetes Index. T1D Index factsheet: GLOBAL. Accessed October 1, 2024. https://t1dindex.shinyapps.io/dashboard/
  60. Type 1 Diabetes Index. A campaign guide to launch the T1D Index. Accessed October 1, 2024. https://www.t1dindex.org/wp-content/uploads/2022/09/Campaign-Guide.pptx-2.pdf
  61. Sims EK, Besser REJ, Dayan C, et al. Screening for type 1 diabetes in the general population: A Status Report and Perspective. Diabetes. 2022;71(4):610-623.
  62. Narendran P. Screening for type 1 diabetes: are we nearly there yet? Diabetologia. 2019;62(1):24-27.
  63. DiMeglio LA, Evans-Molina C and Oram RA. Type 1 diabetes. Lancet. 2018;391(10138):2449-2462.
  64. Ospelt E, Hardison H, Rioles N, et al. Understanding Providers’ Readiness and Attitudes Toward Autoantibody Screening: A Mixed-Methods Study. Clin Diabetes. 2024;42(1):17-26.
  65. ElSayed NA, Aleppo G, Aroda VR, et al. Addendum. 2. Classification and diagnosis of diabetes: Standards of Care in Diabetes-2023. Diabetes Care. 2023;46(Suppl 1):S19-S40.
  66. Ha J, Cree-Green M, Chung ST, et al. Editorial: Metabolic estimates during glucose challenge tests and continuous glucose monitoring-Innovative and broad approaches to assessing glucose and insulin metabolism in diverse populations. Front Physiol. 2022;13:1112502.
Related articles
How to screen for Autoimmune T1D

How to screen for Autoimmune T1D

Read article
Why to screen for Autoimmune T1D

Why to screen for Autoimmune T1D

Read article
The burden of Autoimmune T1D

The burden of Autoimmune T1D

Read article